|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||48.36 - 49.88|
|52-week range||44.02 - 91.35|
|PE ratio (TTM)||N/A|
|Earnings date||14 Feb 2018 - 19 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||66.81|
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
The Novato, California-based company said it had a loss of $1.87 per share. The results matched Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was also ...
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.